Related Experiment Video
Updated: Jan 18, 2026
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023
DNA Methylation in Ovarian and Endometrial Cancers: Predictive and Mechanistic Roles in PARP Inhibitor and ICI
Shuhei Kitamura1, Ayumi Taguchi1, Kana Tamai1
1Department of Obstetrics and Gynecology, The University of Tokyo, Tokyo, Japan.
Abstract:
Cancer treatment is shifting from an organ-based approach to one driven by biological phenotypes, emphasizing the need to understand molecular mechanisms. DNA methylation plays a pivotal role in tumor biology, not only through gene silencing but also by inducing distinct behaviors beyond genetic mutations. In gynecologic cancers, molecular diagnostics, such as homologous recombination deficiency status guiding poly(ADP-ribose) polymerase (PARP) inhibitor therapy in ovarian cancer and deficient mismatch repair/microsatellite instability-high status informing immune checkpoint inhibitor (ICI) therapy in endometrial cancer have already been used in clinical practice. However, tumors with epigenetically driven functional deficiencies, such as BRCA1 promoter methylation in homologous recombination-deficient ovarian cancers or MLH1 promoter methylation in deficient mismatch repair/microsatellite instability-high endometrial cancers, often exhibit poorer prognoses and reduced therapeutic responses compared to their genetically mutated counterparts. Given the unique impact of DNA methylation, precise detection is crucial. Integrating methylation analysis into molecular classification could refine diagnostics-both by identifying mechanistic contributors to treatment response and by serving as predictive biomarkers for therapy selection-thereby optimizing patient management. This review explores the role of DNA methylation in modulating responses to PARP inhibitors and ICIs, highlights its promise as a biomarker in precision oncology, and outlines current developments and clinical challenges in BRCA1 and MLH1 methylation assays.
Insights
DNA methylation significantly impacts gynecologic cancer treatment response. Understanding and detecting DNA methylation is crucial for developing targeted therapies and improving patient outcomes in precision oncology.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Cancer treatment is evolving towards biologically driven approaches, necessitating a deeper understanding of molecular mechanisms.
- DNA methylation is a key epigenetic mechanism influencing tumor biology and behavior beyond genetic mutations.
- Current molecular diagnostics in gynecologic cancers include homologous recombination deficiency (HRD) for PARP inhibitors and mismatch repair deficiency (dMMR)/microsatellite instability-high (MSI-H) for immune checkpoint inhibitors (ICIs).
Purpose of the Study:
- To explore the role of DNA methylation in modulating responses to poly(ADP-ribose) polymerase (PARP) inhibitors and immune checkpoint inhibitors (ICIs).
- To highlight the promise of DNA methylation as a predictive biomarker in precision oncology for gynecologic cancers.
- To outline current developments and clinical challenges in BRCA1 and MLH1 methylation assays.
Main Methods:
- Review of current literature on DNA methylation in gynecologic cancers.
- Analysis of the impact of DNA methylation on therapeutic responses to PARP inhibitors and ICIs.
- Examination of the clinical utility and challenges of methylation-specific assays.
Main Results:
- Epigenetically driven deficiencies (e.g., BRCA1/MLH1 promoter methylation) can lead to poorer prognoses and reduced treatment efficacy compared to genetic mutations.
- DNA methylation analysis holds promise for refining molecular classification and identifying mechanistic contributors to treatment response.
- Precise detection of DNA methylation is crucial for its integration into diagnostic and therapeutic strategies.
Conclusions:
- Integrating DNA methylation analysis into molecular classification can enhance diagnostic precision and optimize patient management in gynecologic oncology.
- DNA methylation serves as a critical biomarker for predicting response to PARP inhibitors and ICIs, advancing precision oncology.
- Further development and standardization of BRCA1 and MLH1 methylation assays are needed for widespread clinical application.
Related Concept Videos
01:37Epigenetic Regulation
X-chromosome...
01:46Epigenetic Regulation
02:07Oogenesis
02:30Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...